- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage...
- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust...
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle...
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term...
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics,...
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts...
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for...